维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

12篇 您的检索式：作者名="WAINBERG Z"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo显示文摘	Wainberg Z A Anghel A Desai A J Ayala R Luo T Safran B	2010	Clin Cancer Res2010，16，：	1
	2	Panitumumab in colon cancer:a review and summary of ongoing trials显示文摘	Wainberg Z Hecht JR		0，，11：	1
	3	Modulation of stress protein (hsp27 and hsp70) espression in CD4 lymphocytic cells following scute infection weth human immunodeficiency virus type-1显示文摘	Oliveira M Lerner S	1997	Virology1997，233，：	1
	4	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA mutation carrier cancer patients 显示文摘	Wainberg Z Rafii S Ramanathan R	2014	J Clin Oncol 32 5S2014，7522，：	1
	5	Lapatinib,a dual EGFR and HER2 kinase inhibitor,selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo显示文摘	Wainberg Z A Anghel A Desai A J	2005	Clin Cancer Res2005，16，5：	1
	6	Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficieney virus type显示文摘	WAINBERG Z OL1VEIRA M LERNER S	1997	Virology1997，233，：	1
	7	Acute lymphoblastic leukemia presenting as acute renal failure显示文摘	SUH W M WAINBERG Z A DE VOS S	2007	Nat Clin Pract Nephrol2007，3，2：	1
	8	Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastm - oe- sophageal junction显示文摘	Wainberg Z A Lin L S DiCarlo B	2011	Br J Cancer2011，105，6：	1
	9	Final results of a phase Ⅱ study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ)显示文摘	Wainberg Z A Lin L DiCarlo B	2010	J Clin Oncol2010，28，15：	1
	10	Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric can-cer(GC): Interim results of a muhicenter phase II study 显示文摘	Jhawer M Kindler HL Wainberg Z	2009	J Clin Oncol2009，27，15：	1
	11	Phase Ⅱ study evaluating 2 dosing schedules of oral foretinib ( GSK1363089 ), oMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer显示文摘	Shah M A Wainberg Z A Catenaeci D V T	2013	PLoS One2013，8，54：	1
	12	Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clini cal review of antiretroviral resistance显示文摘	Callant J E Cerondclis P Z Wainberg M A etal	2003	Antivir Ther2003，8，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费